Anne Altmeyer
Biotech executive and board director in oncology and immunology
Boston, Massachusetts
Summary
Seasoned biotech executive and CEO: Anne Altmeyer leads TigaTx as President and CEO, guiding development of engineered IgA monoclonal antibody programs and securing non-dilutive government funding to advance clinical-stage activities. tigatx+1
Business development and licensing leader across pharma and biotech: She has held senior BD and C-suite business roles at Novartis, Baxalta, Adicet and Sigilon, focusing on strategic transactions, negotiations and alliance management to advance oncology and immunology portfolios. prnewswire+1
Scientist with formal immunology training and publications: She holds a Ph.D. in molecular immunology from Université Louis Pasteur and completed postdoctoral fellowships at NYU School of Medicine and Cornell University Medical College, and is an author on peer-reviewed immunology and molecular biology research. corbuspharma+1
Corporate governance and board experience: Appointed to the Corbus Pharmaceuticals board in September 2022 and serves as an independent director; also reported as joining other boards and participating in standard non-employee director governance and compensation practices. corbuspharma+1
Work
Education
Projects
Writing
TRAIL/Apo-2 ligand induces primary plasma cell apoptosis
November 1, 2002Research article describing the role of TRAIL/Apo-2 ligand and death receptors in inducing apoptosis of primary plasma cells.
Promoter Structure and Transcriptional Activation of the Murine TSG-14 Gene
October 27, 1995Article (Journal of Biological Chemistry) on promoter structure and regulation of TSG-14 (PTX3) expression.